(Total Views: 666)
Posted On: 05/07/2021 7:13:35 AM
Post# of 153907
new pre-print from china
" To ensure better clinical outcomes in COVID-19 patients, new drugs with potent anti-inflammatory capacity are urgently needed, especially for those with metabolic comorbidities. Several drugs targeting inflammation, including tocilizumab, sarilumab, siltuximab (IL-6 receptor antagonist monoclonal antibodies), anakinra (IL-1 inhibitors), the Janus kinase inhibitors fedratinib and baricitinib, and the C-C chemokine receptor type 5 (CCR5) antagonist leronlimab are all being trialed in COVID-19 patients. "
https://www.sciencedirect.com/science/article...2221004674
" To ensure better clinical outcomes in COVID-19 patients, new drugs with potent anti-inflammatory capacity are urgently needed, especially for those with metabolic comorbidities. Several drugs targeting inflammation, including tocilizumab, sarilumab, siltuximab (IL-6 receptor antagonist monoclonal antibodies), anakinra (IL-1 inhibitors), the Janus kinase inhibitors fedratinib and baricitinib, and the C-C chemokine receptor type 5 (CCR5) antagonist leronlimab are all being trialed in COVID-19 patients. "
https://www.sciencedirect.com/science/article...2221004674
(8)
(0)
